title: Tricky FDA debate: should a risky drug be approved again?
authors.forename: Anna Wilde
authors.initials: AW
authors.lastname: Mathews
authors.forename: Sylvia Pagan
authors.initials: SP
authors.lastname: Westphal
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000009:adverse effects* / Q000633:toxicity; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D018579:Patient Selection; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015507:Drugs, Investigational; D000069442:Natalizumab